April 18th 2024
A novel scoring system including radiomics data may help clinicians identify the risk of central lymph node metastasis in patients with a subtype of thyroid cancer.
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
T-Cell Lymphopenia Linked to Poor Prognosis in Advanced Thyroid Cancer
March 29th 2019Recently published data from a retrospective study suggest that patients with thyroid cancer who have T-cell lymphopenia are more likely to have aggressive tumors. Investigators believe this information can be used to identify potential therapeutic targets in these patients.
Read More
Radiation Expert Highlights Role of Radioactive Iodine in Differentiated Thyroid Cancer
March 29th 2019Radiation oncologist Jimmy J. Caudell, MD, PhD,discusses the role of radioactive iodine therapy in patients with DTC. He also highlights areas of research that may help determine the best treatment regimens and doses for select patients.
Read More
New Study Finds That 2.5% of Follicular Thyroid Carcinomas Are MSI-High
March 28th 2019A comprehensive effort to assess the prevalence of microsatellite instability in a large series of malignant thyroid tumors comprising all major histologic subtypes has found that the overall prevalence of MSI in follicular thyroid cancer is 2.5%. The study also found that MSI is either entirely absent or rare in other histology subtypes of thyroid carcinoma.
Read More
CMS Mulls Opposition to Downsizing Part D Protected Drug Classes
March 15th 2019The healthcare community is still awaiting a response from the Centers for Medicare & Medicaid Services to the opposition of the agency’s proposal to substantially revise the Medicare Part D protected drug classes.
Read More
Avoiding Overtreatment Saves Medicare $320M Over 3-Year Period in Older Men With Prostate Cancer
March 13th 2019Overtreating men 70 years or older with prostate cancer cost Medicare more than $1.2 billion from 2004 to 2007, according to the results of a retrospective study using the Surveillance, Epidemiology, and End Results–Medicare linked database.
Read More
Targeted Therapies Advancing Thyroid Cancer Treatment Paradigm
March 1st 2019Lori J. Wirth, MD, discusses the current treatment options for patients with advanced thyroid cancers, in addition to some of the trials that are currently enrolling at her center. She also highlights early data that have been presented for targeted therapies in advanced thyroid cancer.
Read More
Frequency of RET Alterations in Thyroid Cancers
February 28th 2019Lori J. Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital, discusses how common RET alterations are in thyroid cancers.
Watch
Adjuvant Radiation Associated with Worse OS, DSS in Papillary Thyroid Cancer
February 28th 2019Adjuvant external beam radiation therapy was associated with worse overall survival and disease-specific survival in patients with locally invasive papillary thyroid carcinoma, a new retrospective cohort study has found.
Read More
Positive Findings Seen With Lenvatinib in Two Difficult-to-Treat Thyroid Cancer Subtypes
February 14th 2019Lenvatinib demonstrated promising antitumor activity and a manageable toxicity profile in 3 main subtypes of thyroid cancer, according to findings recently published in <em>Future Oncology.</em>
Read More
Positive RET Staining Associated with Low Risk of Recurrence, Death in Thyroid Cancer
January 30th 2019Positive RET staining by immunohistochemistry was associated with a low risk of recurrence and death from papillary thyroid cancer, according to a new exploratory analysis published in <em>Cancer Medicine</em> that examined a cohort of 231 patients with long-term follow up at a single institution.
Read More
TERT Mutations Indicative of Poor Outcomes in Non-Aggressive Thyroid Cancer
January 23rd 2019A prospective, observational study recently published in the <em>European Journal of Cancer </em>helped to clarify the prognostic role of <em>TERT </em>promoter mutations among patients with localized thyroid cancer, revealing that <em>TERT </em>mutations were associated with poor outcomes among patients with nonmetastatic disease that do not have an aggressive histology.
Read More